AIM ImmunoTech issues letter to stockholders

AIM ImmunoTech issued a letter to stockholders highlighting key accomplishments in 2022 and outlining corporate objectives for 2023. "Over the course of the past year, the AIM management team and Board have worked dedicatedly to position the Company for continued success… We have continued to be encouraged by the data we have seen to date demonstrating Ampligen’s potential for the treatment of multiple types of cancers, immune disorders, and viral diseases, including COVID-19, and continue to establish a growing body of data as a priority. With 10 active clinical programs, 2023 is poised to be a busy and exciting year. In addition to a number of publications for pipeline data expected throughout the year, anticipated upcoming milestones include: Q1 2023: Post-COVID Conditions: Commence Phase 2 study; Locally Advanced Pancreatic Cancer: Enroll first patient in Phase 2 study. Q2 2023: Locally Advanced Pancreatic Cancer: Dose first patient in Phase 2 study; Post-COVID Conditions: Enroll and dose first patient in Phase 2 study. Q3 2023: Advanced Recurrent Ovarian Cancer: Announce Formal interim results. Q4 2023: Metastatic Pancreatic Cancer: Begin clinical trial: Post-COVID Conditions: Complete patient enrollment in Phase 2 study. In addition to executing on our clinical development, we have a number of corporate initiatives we are committed to in 2023, which include building diversity among our Board of Directors. We are actively working to identify individuals with key leadership and expertise and look forward to providing updates as those plans come to fruition. Another priority for us is to maintain active communication with the investment community. With this in mind, we plan to commence quarterly conference calls in the first quarter of 2023."